The Inhibitory Effect of Hydroalcoholic Extract of Black Punica Granatum Pericarp on the Number of Endothelial Progenitor Cells (EPCs) in Melanoma through Peroxisome Proliferator-Activated Receptor-α and γ (PPAR-α and γ) Pathways in C57BL6 Mice

Document Type : Original Article (s)

Authors

1 Applied Physiology Research Center AND Department of Physiology, School of Medicine AND Pharmaceutical Sciences Research Center, School of Pharmacy, Isfahan University of Medical Sciences, Isfahan, Iran

2 Applied Physiology Research Center AND Department of Physiology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

3 Associate Professor, Applied Physiology Research Center AND Department of Physiology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: Endothelial progenitor cells (EPCs) play an important role in tumor growth and angiogenesis. Punica granatum, from Punicaceae family, has demonstrated anticancer effects in different types of cancers. This study aimed to determine the effect of hydroalcoholic extract of pomegranate peel on the number of EPCs in mouse model of melanoma and also to determine its mechanism of action.Methods: The hydroalcoholic extract of black pomegranate pericarp was prepared using 70% ethanol containing 1% acetic acid. 1 × 106 B16F10 melanoma cells were injected to each of 88 C57BL6 male mice weighing 25 g on the day 0, subcutaneously (s.c). On 7th day, mice were randomly divided into 11 groups of 8 animals. The first group (control) received distilled water. Groups second to fifth from the seventh day of the study received 50, 100, 200 and 400 mg/kg of standardized polyphenon E (PPE) via gavage. The sixth group received PPE and peroxisome proliferator-activated receptor gamma (PPAR-γ) antagonist (5 mg/kg/day) intraperitoneally. The seventh group received PPE and PPAR-α antagonist (10 mg/kg/day) intraperitoneally. Eighth and ninth groups received fenofibrate (100 mg/kg) and rosiglitazone (100 mg/kg) as agonists of PPAR-α and PPAR-γ, respectively, via gavage. Tenth and eleventh groups received PPAR antagonists, merely. On 16th day, mice were euthanized and were bled through heart puncture for EPC enumeration via flow cytometry. In flow cytometry, CD34+/VEGFR2+ cells were enumerated.Findings: PPE dose-dependently decreased the number of EPCs (P < 0.05). Number of EPCs in the groups which received fenofibrate and rosiglitazone was less than the group that received the highest dose of PPE (P < 0.05). Moreover, EPCs in the groups which received both PPAR antagonists and PPE, was more than the group which received PPE (P < 0.01).Conclusion: In conclusion, we demonstrated that PPE is effective in reducing the number of EPCs and part of this effect is through modulation of PPAR pathway.

Keywords

References

  1. Abe R, Fujita Y, Yamagishi S. Angiogenesis and metastasis inhibitors for the treatment of malignant melanoma. Mini Rev Med Chem 2007; 7(6): 649-61.
  2. Oh SH, Woo JK, Jin Q, Kang HJ, Jeong JW, Kim KW, et al. Identification of novel antiangiogenic anticancer activities of deguelin targeting hypoxia-inducible factor-1 alpha. Int J Cancer 2008; 122(1): 5-14.
  3. Mahabeleshwar GH, Byzova TV. Angiogenesis in melanoma. Semin Oncol 2007; 34(6): 555-65.
  4. Ribatti D, Nico B, Floris C, Mangieri D, Piras F, Ennas MG, et al. Microvascular density, vascular endothelial growth factor immunoreactivity in tumor cells, vessel diameter and intussusceptive microvascular growth in primary melanoma. Oncol Rep 2005; 14(1): 81-4.
  5. Dome B, Hendrix MJ, Paku S, Tovari J, Timar J. Alternative vascularization mechanisms in cancer: Pathology and therapeutic implications. Am J Pathol 2007; 170(1): 1-15.
  6. Asahara T, Masuda H, Takahashi T, Kalka C, Pastore C, Silver M, et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 1999; 85(3): 221-8.
  7. Goon PK, Lip GY, Boos CJ, Stonelake PS, Blann AD. Circulating endothelial cells, endothelial progenitor cells, and endothelial microparticles in cancer. Neoplasia 2006; 8(2): 79-88.
  8. Mellick AS, Plummer PN, Nolan DJ, Gao D, Bambino K, Hahn M, et al. Using the transcription factor inhibitor of DNA binding 1 to selectively target endothelial progenitor cells offers novel strategies to inhibit tumor angiogenesis and growth. Cancer Res 2010; 70(18): 7273-82.
  9. Lyden D, Hattori K, Dias S, Costa C, Blaikie P, Butros L, et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 2001; 7(11): 1194-201.
  10. Pfisterer PH, Wolber G, Efferth T, Rollinger JM, Stuppner H. Natural products in structure-assisted design of molecular cancer therapeutics. Curr Pharm Des 2010; 16(15): 1718-41.
  11. Jurenka JS. Therapeutic applications of pomegranate (Punica granatum L.): a review. Altern Med Rev 2008; 13(2): 128-44.
  12. Lansky EP, Newman RA. Punica granatum (pomegranate) and its potential for prevention and treatment of inflammation and cancer. J Ethnopharmacol 2007; 109(2): 177-206.
  13. Sartippour MR, Seeram NP, Rao JY, Moro A, Harris DM, Henning SM, et al. Ellagitannin-rich pomegranate extract inhibits angiogenesis in prostate cancer in vitro and in vivo. Int J Oncol 2008; 32(2): 475-80.
  14. Toi M, Bando H, Ramachandran C, Melnick SJ, Imai A, Fife RS, et al. Preliminary studies on the anti-angiogenic potential of pomegranate fractions in vitro and in vivo. Angiogenesis 2003; 6(2): 121-8.
  15. Khan N, Hadi N, Afaq F, Syed DN, Kweon MH, Mukhtar H. Pomegranate fruit extract inhibits prosurvival pathways in human A549 lung carcinoma cells and tumor growth in athymic nude mice. Carcinogenesis 2007; 28(1): 163-73.
  16. Adams LS, Seeram NP, Aggarwal BB, Takada Y, Sand D, Heber D. Pomegranate juice, total pomegranate ellagitannins, and punicalagin suppress inflammatory cell signaling in colon cancer cells. J Agric Food Chem 2006; 54(3): 980-5.
  17. Berger J, Moller DE. The mechanisms of action of PPARs. Annu Rev Med 2002; 53: 409-35.
  18. Panigrahy D, Kaipainen A, Huang S, Butterfield CE, Barnes CM, Fannon M, et al. PPARalpha agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition. Proc Natl Acad Sci U S A 2008; 105(3): 985-90.
  19. Yasui Y, Kim M, Tanaka T. PPAR Ligands for Cancer Chemoprevention. PPAR Res 2008; 2008: 548919.
  20. Eastham LL, Mills CN, Niles RM. PPARalpha/gamma expression and activity in mouse and human melanocytes and melanoma cells. Pharm Res 2008; 25(6): 1327-33.
  21. Freudlsperger C, Schumacher U, Reinert S, Hoffmann J. The Critical Role of PPARgamma in Human Malignant Melanoma. PPAR Res 2008; 2008: 503797.
  22. Ni Q, Xu G, Lu G, Gao Q, Zhou C, Zhang Y. Investigation of the stability and antioxidant properties of anthocyanins-based purple potato colorants after processing. Afr J Biotechnol 2012; 11(14): 3379-87.
  23. Oancea S, Draghici O. pH and thermal stability of anthocyanin-based optimised extracts of Romanian Red onion cultivars. Czech Journal of Food Science 2013; 31(3): 283-91
  24. Downer EJ, Clifford E, Amu S, Fallon PG, Moynagh PN. The synthetic cannabinoid R(+)WIN55,212-2 augments interferon-beta expression via peroxisome proliferator-activated receptor-alpha. J Biol Chem 2012; 287(30): 25440-53.
  25. Nakajima A, Tomimoto A, Fujita K, Sugiyama M, Takahashi H, Ikeda I, et al. Inhibition of peroxisome proliferator-activated receptor gamma activity suppresses pancreatic cancer cell motility. Cancer Sci 2008; 99(10): 1892-900.
  26. Javanmard Sh, Gheisari Y, Soleimani M, Nematbakhsh M, Monajemi A. Effect of L-arginine on circulating endothelial progenitor cells in hypercholesterolemic rabbits. Int J Cardiol 2010; 143(2): 213-6.
  27. Rehman J, Li J, Orschell CM, March KL. Peripheral blood "endothelial progenitor cells" are derived from monocyte/macrophages and secrete angiogenic growth factors. Circulation 2003; 107(8): 1164-9.
  28. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997; 275(5302): 964-7.
  29. Kalka C, Masuda H, Takahashi T, Kalka-Moll WM, Silver M, Kearney M, et al. Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. Proc Natl Acad Sci U S A 2000; 97(7): 3422-7.
  30. Dana N, Haghjooy Javanmard Sh, Fazilati M, Pilehvarian A. Anti-angiogenic effects of pomegranate peel extract (punica granatum l.) on human umbilical vein endothelial cells. J Isfahan Med Sch 2012; 30(195): 913-21. [In Persian].
  31. Fotsis T, Pepper MS, Montesano R, Aktas E, Breit S, Schweigerer L, et al. Phytoestrogens and inhibition of angiogenesis. Baillieres Clin Endocrinol Metab 1998; 12(4): 649-66.
  32. Le ML. Cancer preventive effects of flavonoids--a review. Biomed Pharmacother 2002; 56(6): 296-301.
Journal of Isfahan Medical School
Volume 33, Issue 334 - Serial Number 334
March and April 2015
Pages 685-693

Files

History

  • Receive Date: 26 February 2015
  • Revise Date: 01 November 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics